Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
85 hedge funds and large institutions have $40.4M invested in Kezar Life Sciences in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 11 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
5% more funds holding
Funds holding: 81 → 85 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.85% less ownership
Funds ownership: 67.94% → 63.09% (-4.8%)
14% less capital invested
Capital invested by funds: $46.8M → $40.4M (-$6.36M)
21% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$1.6M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
+$629K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$487K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$348K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$2.19M |
| 2 |
Millennium Management
New York
|
-$1.92M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.81M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$836K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$579K |
KZR Hedge Fund Activity: Q1 2024 in Review
85 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2024, worth a combined $40.4M — down 14% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KZR positions and 11 closed out — a net gain of 4 holders — while 23 added to existing stakes and 29 trimmed.
The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $1.6M. The largest seller was Prosight Management, cutting an estimated $2.19M.
- 85 institutional investors held Kezar Life Sciences (KZR) as of Q1 2024, up from 81 in Q4 2023.
- Funds reported $40.4M of Kezar Life Sciences stock for Q1 2024, down 14% quarter-over-quarter.
- 15 funds opened new Kezar Life Sciences positions in Q1 2024 and 11 closed out, a net change of +4 holders.
- The largest Kezar Life Sciences buyer in Q1 2024 was Affinity Asset Advisors, an estimated $1.6M added.
- The largest Kezar Life Sciences seller in Q1 2024 was Prosight Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2024.